Group 1 - Baiyunshan Holdings' subsidiary Guangzhou Pharmaceutical Co., Ltd. will be listed on the New Third Board starting May 20, 2025, marking a significant step in capital operations for Baiyunshan [1] - The listing is expected to broaden financing channels and enhance brand influence, as Guangzhou Pharmaceutical is a leading pharmaceutical distribution company in South China [1] - However, the New Third Board has relatively low liquidity, necessitating the optimization of governance structures and strengthening of profitability to attract long-term capital [1] Group 2 - Dezhan Health has signed a cooperation framework agreement with Academician Yang Baofeng to establish an academician expert workstation at its subsidiary, Deyi Pharmaceutical Co., Ltd. [2] - This collaboration aims to enhance the company's drug development capabilities in the cannabinoid innovation drug field [2] - The development of cannabinoid drugs is noted to have long cycles and strict regulations, requiring attention to clinical progress and commercialization capabilities [2] Group 3 - BeiGene has registered a Phase Ib clinical trial for BGB-16673, a BTK degrader targeting chronic spontaneous urticaria, marking it as the first autoimmune disease trial for this drug [3] - BGB-16673 is the fastest progressing BTK degrader in clinical development and has the potential to address resistance issues associated with existing BTK inhibitors [3] - The expansion into autoimmune indications opens up broader market opportunities and validates the application potential of the CDAC platform across multiple disease areas [3]

药品行业趋势快报 2025年1-4月 数据来源 p 硬广统计平台：央卫视49频道（2024年4月1日起新增CCTV-17农业农村频道监测，共计49个央卫视频道） p 综艺统计平台：电综：央卫视49频道（2024年4月1日起新增CCTV-17农业农村频道监测，共计49个央卫视频道） 网综-爱优腾芒等主流视频平台 p 网剧统计平台：爱奇艺、优酷、腾讯视频、芒果TV等四大平台，剧集播出首轮品牌监测 p 网剧合作类型：剧内植入-影视剧剧内品牌植入，指口播、片尾鸣谢、置景道具、互动道具等资源；平台自招商：指 标板、角标、预告/回顾、创可贴、创意中插、片尾彩蛋、明星播报、压屏条、内容提示等资源 p 报告中客户数量均按照厂商数统计；报告中去除非商业合作客户：音乐、视频、场地合作、新浪等非商业客户 p 报告统计周期：2025年1月-4月 硬广-药品客户在央视系列频道投放数量及时长均领先，投放时长占比超58% 数据来源：击壤科技 2025年1-4月 央卫视49频道硬广 • 截至25年4月，药品硬广客户数（厂商数）共计191个，投放时长总计3,214,104 秒；从媒体层级看，多投放央视系列频道，央视频道投放时长占比高达58.1 ...

Core Viewpoint - The article discusses the serious disciplinary violations and illegal activities of Li Chuyuan, the former Party Secretary and Chairman of Guangzhou Pharmaceutical Group Co., Ltd., leading to his expulsion from the Party and removal from public office [2][3]. Group 1: Disciplinary Actions - Li Chuyuan was expelled from the Party and removed from public office due to severe violations of political, organizational, and ethical disciplines, constituting serious job-related crimes [3]. - His illegal activities included engaging in superstitious practices, misuse of public resources, and accepting bribes, which were investigated by the Guangdong Provincial Commission for Discipline Inspection [2][3]. Group 2: Company Background - Guangzhou Pharmaceutical Group Co., Ltd. is a state-owned enterprise authorized by the Guangzhou government, involved in the research, production, and sales of traditional Chinese medicine, chemical drugs, and health products [5]. - The company operates several well-known brands, including "Wanglaoji" and "Baiyunshan," with significant brand values of 108 billion and 28.3 billion respectively [5]. Group 3: Li Chuyuan's Career - Li Chuyuan has held various positions within the company since 1988, eventually becoming the Chairman in 2013, and has been recognized with multiple awards and honors throughout his career [6][7]. - His public statements during events, particularly regarding the efficacy of the company's products, have sparked controversy and debate [7].

Group 1 - The core viewpoint of the articles highlights the successful establishment of the Gansu Guangyao Baiyunshan Traditional Chinese Medicine Technology Co., Ltd. in Longxi, showcasing effective collaboration between government and enterprises to boost local industry [1][2] - The project is expected to generate significant revenue, with sales projected to exceed 500 million yuan in 2024 and reach 200 million yuan by 2025, indicating strong market demand for its products [1] - Longxi County has implemented a "three-pronged" service mechanism to facilitate investment projects, resulting in 158 projects with a total investment of 28.43 billion yuan over the past three years [2] Group 2 - Longxi County, known for its rich history in traditional Chinese medicine, has faced challenges due to a lack of deep processing enterprises, which has hindered the development of its medicinal industry [2] - The collaboration between Guangyao Group and Longxi County is seen as a turning point, injecting capital and restructuring the industrial ecosystem, thus addressing the previous bottlenecks in the local industry [2] - The county has adopted customized policies to support enterprises at various growth stages, securing over 34.4 million yuan in technology funding from provincial and municipal sources in the past three years [2]

Group 1 - The establishment of the headquarters of Wanglaoji Health Company on Guangzhou International Bio Island marks a strategic upgrade towards a technology-driven health enterprise for the Guangzhou Pharmaceutical Group [1][3] - Guangzhou International Bio Island has gathered over 500 top research institutions and companies, positioning itself as a "golden track" for the health industry and a test of competitiveness [3] - The relocation of the headquarters is not just a spatial change but aims to leverage the "Lighthouse Effect" of Bio Island to accelerate scientific research innovation and digital transformation [3] Group 2 - Wanglaoji signed a strategic cooperation agreement with South Korea's Nongshim Group, focusing on channel sharing, brand promotion, and joint product and technology development [4] - This partnership is the first international collaboration project following Wanglaoji's move to the Bio Island headquarters, highlighting the dual strategy of technology enhancement and globalization [4] - The collaboration aims to enhance product capabilities through Bio Island's research resources while leveraging Nongshim's international market presence to facilitate global competition for Chinese health beverages [4]

Core Viewpoint - The high-quality performance of the Gaozhou Puppet Show, a national intangible cultural heritage, attracted a large audience at the event held in Guangzhou's Baiyun Mountain, showcasing the cultural richness and innovative spirit of the art form [1][5][19]. Group 1: Event Overview - On May 1, the Gaozhou Puppet Show performed "Xian Tai Lian Bing" at Baiyun Mountain, drawing significant attention from citizens and tourists [2][8]. - The event featured various performances, including "Nezha," "Retro Disco," and "Tang Gu La Feng Bao," which combined traditional puppet techniques with contemporary themes to engage younger audiences [16][18]. Group 2: Cultural Significance - Gaozhou Puppet Show, also known as "Gui Zi Xi," was recognized as a national intangible cultural heritage in 2006, highlighting its historical and cultural importance [20][21]. - The show has a strong local support system, with 2 national-level inheritors, 4 city-level, and 5 county-level inheritors, along with a puppet association comprising over 500 members and 132 puppet troupes [21][22]. Group 3: Audience Engagement - The audience actively participated in the event, capturing performances on their phones and engaging in interactive games, which contributed to the lively atmosphere [4][29]. - The event also included a promotional segment for Gaozhou's agricultural and cultural tourism products, with over 40 enterprises showcasing more than 100 products [31][32]. Group 4: Agricultural Promotion - Gaozhou, known as the "Hometown of Lychee," produces over 500,000 tons of lychee annually, accounting for one-fourth of China's total lychee production [36]. - The city launched customized lychee activities targeting various groups, enhancing community engagement and promoting local agricultural products [38][43].

Performance Summary - Industrial and Commercial Bank of China (01398.HK) reported Q1 revenue of 204.688 billion yuan, a decrease of 2.61% year-on-year, and a net profit of 84.156 billion yuan, down 3.99% [3] - China Construction Bank (00939.HK) had Q1 operating income of 185.99 billion yuan, down 4.76% year-on-year, with a net profit of 83.351 billion yuan, also down 3.99% [3] - Agricultural Bank of China (01288.HK) achieved Q1 revenue of 186.735 billion yuan, an increase of 0.32% year-on-year, and a net profit of 71.931 billion yuan, up 2.2% [3] - Bank of China (03988.HK) reported Q1 revenue of 164.911 billion yuan, an increase of 2.41% year-on-year, but a net profit of 58.644 billion yuan, down 2.22% [3] - Postal Savings Bank of China (01658.HK) had Q1 revenue of 89.406 billion yuan, a slight decrease of 0.1%, and a net profit of 25.246 billion yuan, down 2.62% [3] - China Merchants Bank (03968.HK) reported Q1 revenue of 83.731 billion yuan, down 3.11% year-on-year, with a net profit of 37.286 billion yuan, down 2.08% [3] - Bank of Communications (03328.HK) had Q1 net operating income of 66.44 billion yuan, down 1.13%, but a net profit of 25.372 billion yuan, up 1.54% [3] - HSBC Holdings (00005.HK) reported Q1 revenue of 17.649 billion USD, down 14.95%, and a post-tax profit of 7.57 billion USD, down 30.15% [3] - China People's Insurance Group (01339.HK) achieved Q1 revenue of 156.589 billion yuan, up 12.8%, and a net profit of 12.849 billion yuan, up 43.4% [3] - China Life Insurance (02628.HK) reported Q1 revenue of 110.177 billion yuan, down 8.9%, but a net profit of 28.802 billion yuan, up 39.5% [3] - New China Life Insurance (01336.HK) had Q1 revenue of 33.402 billion yuan, up 26.1%, and a net profit of 5.882 billion yuan, up 19% [3] - China National Petroleum Corporation (00857.HK) reported Q1 revenue of 753.108 billion yuan, down 7.3%, but a net profit of 46.809 billion yuan, up 2.3% [3] - CNOOC (00883.HK) had Q1 revenue of 106.854 billion yuan, down 4.1%, and a net profit of 36.563 billion yuan, down 7.9% [3] - Huadian International Power (01071.HK) reported Q1 revenue of 26.577 billion yuan, down 14.14%, but a net profit of 1.93 billion yuan, up 3.66% [3] - China International Marine Containers (01880.HK) had Q1 revenue of 16.746 billion yuan, down 10.96%, and a net profit of 1.938 billion yuan, down 15.98% [3] - Air China (00753.HK) reported Q1 revenue of 40.023 billion yuan, down 0.11%, with a net loss of 2.044 billion yuan, an increase of 22.07% [3] - CITIC Securities (06030.HK) achieved Q1 revenue of 17.761 billion yuan, up 29.13%, and a net profit of 6.545 billion yuan, up 32% [3] - China Galaxy Securities (06881.HK) reported Q1 revenue of approximately 7.558 billion yuan, up 4.77%, and a net profit of approximately 3.016 billion yuan, up 84.86% [3] - CITIC Construction Investment Securities (06066.HK) had Q1 operating income of 4.919 billion yuan, up 14.54%, and a net profit of 1.843 billion yuan, up 50.07% [3] - Huatai Securities (06886.HK) reported Q1 revenue of approximately 8.232 billion yuan, up 34.83%, and a net profit of approximately 3.642 billion yuan, up 58.97% [3] - China Railway Construction (01186.HK) had Q1 revenue of 256.762 billion yuan, down 6.61%, and a net profit of 5.151 billion yuan, down 14.51% [3] - China Energy Engineering (03996.HK) reported Q1 revenue of 100.371 billion yuan, up 3.05%, and a net profit of 1.612 billion yuan, up 8.83% [3] - Times Electric (03898.HK) achieved Q1 revenue of 4.537 billion yuan, up 14.81%, and a net profit of 631 million yuan, up 13.42% [3] - Midea Group (00300.HK) reported Q1 revenue of 127.839 billion yuan, up 20.49%, and a net profit of 12.422 billion yuan, up 38.02% [3] - WH Group (00288.HK) had Q1 revenue of 6.554 billion USD, up 6.0%, and a profit of 364 million USD, up 20.9% [3] - Suncity Group (00880.HK) reported Q1 total revenue of 7.48 billion HKD, up 8.1%, and a net profit of 31 million HKD, turning profitable [3] - COSCO Shipping Ports (01199.HK) had Q1 revenue of 3.82 billion USD, up 14.7%, and a net profit of 839 million USD, up 33.5% [3] - Flat Glass Group (06865.HK) reported Q1 revenue of 4.079 billion yuan, down 28.76%, and a net profit of 106 million yuan, down 86.03% [3] - Zoomlion Heavy Industry (01157.HK) achieved Q1 revenue of 12.117 billion yuan, up 2.92%, and a net profit of 1.41 billion yuan, up 53.98% [3] - Ganfeng Lithium (01772.HK) reported Q1 revenue of approximately 3.772 billion yuan, down 25.43%, with a net loss of approximately 356 million yuan, narrowing by 18.93% [3] - Qingdao Port (06198.HK) had Q1 revenue of 4.807 billion yuan, up 8.51%, and a net profit of 1.402 billion yuan, up 6.51% [3] - China Shipbuilding Defense (00317.HK) reported Q1 revenue of approximately 3.641 billion yuan, up 29.73%, and a net profit of approximately 184 million yuan, up about 11 times [3] - Baiyunshan Pharmaceutical (00874.HK) had Q1 revenue of 22.473 billion yuan, down 2.06%, and a net profit of 1.821 billion yuan, down 6.99% [3] Investment Activities - New China Life Insurance (01336.HK) plans to invest no more than 10 billion yuan to subscribe to a private fund [4] - China Life Insurance (02628.HK) intends to invest 2 billion yuan to establish a partnership [4] Contract Signing - China Metallurgical Group (01618.HK) reported a new contract signing amount of 230.66 billion yuan in Q1, a decrease of 27.2% year-on-year, with overseas contracts amounting to 12.04 billion yuan, down 35.7% [5] Energy Production - Xin Tian Green Energy (00956.HK) completed power generation of 4.5442 million MWh in Q1, an increase of 10.37% year-on-year [6] - China Power (02380.HK) reported total electricity sales of 30.7477 million MWh in the first three months, up 2.59% year-on-year, with March sales of 10.9617 million MWh, up 3.95% [6] - Qingdao Port (06198.HK) achieved a total cargo throughput of 177 million tons in the first three months, up 2.9% year-on-year [6] Licensing Agreement - Fuhong Hanlin (02696.HK) entered into a licensing agreement with Sandoz AG for the commercialization of HLX13 in specified regions [6] Privatization Offer - Dingsheng Creation (00113.HK) received a privatization offer at a premium of approximately 50.63%, with a maximum cash consideration of about 1.0986 billion HKD [7] Share Buybacks - AIA Group (01299.HK) repurchased shares for 342.6 million HKD, buying back 6.2592 million shares at prices between 54.25 and 55.35 HKD [8] - J&T Express-W (01519.HK) repurchased shares for 9.2485 million HKD, buying back 1.54 million shares at prices between 5.98 and 6.03 HKD [8]

Financial Performance - The company's operating revenue for Q1 2025 was CNY 22,473,408,393, a decrease of 2.06% compared to CNY 22,946,211,892 in the same period last year[4]. - Net profit attributable to shareholders was CNY 1,821,313,254, down 6.99% from CNY 1,958,118,124 year-on-year[4]. - Basic and diluted earnings per share were both CNY 1.120, a decrease of 6.99% from CNY 1.204 in the same period last year[4]. - Total operating revenue for Q1 2025 was CNY 22,473,408,392.77, a decrease of 2.06% from CNY 22,946,211,891.84 in Q1 2024[20]. - Net profit for Q1 2025 was CNY 1,857,449,310.65, a decrease of 8.54% compared to CNY 2,031,724,927.91 in Q1 2024[21]. - The company’s total comprehensive income for Q1 2025 was CNY 1,850,877,925.86, down from CNY 2,033,231,749.61 in Q1 2024[22]. Cash Flow - The net cash flow from operating activities was negative CNY 3,897,258,025, representing a decline of 24.19% compared to the previous year[4]. - Cash inflow from operating activities in Q1 2025 was CNY 15,913,593,244.88, compared to CNY 16,789,987,378.48 in Q1 2024[23]. - The net cash flow from operating activities was negative at (3,897,258,025.12), compared to (3,138,186,616.77) in the previous period, indicating a decline in operational cash generation[24]. - The total cash and cash equivalents at the end of the period decreased to 12,699,134,891.11 from 18,344,448,005.36, reflecting a significant reduction in liquidity[25]. - The company reported a total cash outflow from operating activities of 19,810,851,270.00, slightly down from 19,928,173,995.25, suggesting stable operational expenses[24]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 80,047,799,450, a decrease of 2.00% from CNY 81,683,611,521 at the end of the previous year[6]. - The company's current assets totaled ¥55,673,034,339.05, down from ¥57,762,228,309.37, indicating a decrease of about 3.63%[16]. - Total liabilities decreased to ¥40,408,879,746.27 from ¥43,913,975,774.25, a decline of about 8.5%[17]. - The non-current liabilities decreased to ¥4,299,969,166.95 from ¥4,998,286,418.68, indicating a reduction of about 14.0%[17]. Shareholder Information - The equity attributable to shareholders increased by 5.05% to CNY 37,719,037,765 from CNY 35,904,527,869 at the end of the previous year[6]. - The total number of ordinary shareholders at the end of the reporting period was 93,536[12]. - The largest shareholder, Guangzhou Pharmaceutical Group Co., Ltd., held 45.04% of the shares, totaling 732,305,103 shares[12]. Operational Efficiency - The weighted average return on net assets was 4.95%, down 0.5 percentage points from 5.45% at the end of the previous year[6]. - Research and development expenses for Q1 2025 were CNY 143,713,072.16, a decrease of 22.73% from CNY 186,139,000.55 in Q1 2024[20]. - The company paid 1,669,345,024.24 in cash to employees, a decrease from 1,744,322,516.63, indicating cost management efforts[24]. Investment Performance - The company reported an investment income of CNY 131,136,370.42, up from CNY 102,119,649.77 in Q1 2024[20]. - Cash inflow from investment income was 63,221,276.30, up from 32,695,487.98, reflecting improved investment performance[24]. Other Information - The company has not reported any new strategies or product developments during this period[14]. - The impact of exchange rate changes on cash and cash equivalents was positive at 6,328,259.74, compared to 2,432,159.43 previously, indicating some currency gains[24].

证券代码：600332 证券简称：白云山 公告编号：2025－036 广州白云山医药集团股份有限公司 关于续聘会计师事务所的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对 其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 2、人员信息 首席合伙人为谢泽敏。截至 2024 年 12 月 31 日，大信从业人员总数 3,957 人，其中合伙人 175 人，注册会计师 1,031 人。注册会计师中，超 过 500 人签署过证券服务业务审计报告。 3、业务规模 2023 年度业务收入 15.89 亿元（人民币，下同），为超过 10,000 家 公司提供服务。业务收入中，审计业务收入 13.80 亿元、证券业务收入 4.50 亿元。2023 年上市公司年报审计客户 204 家（含 H 股），平均资产 额 146.53 亿元，收费总额 2.41 亿元。主要分布于制造业、信息传输、软 件和信息技术服务业，电力、热力、燃气及水生产和供应业，科学研究和 1 技术服务业，水利、环境和公共设施管理业。广州白云山医药集团股份有 限公司（"白云山"、"本公司"）同行业上市公司审计 ...

1 附：董事候选人简历 一、程洪进先生 本事项尚需提交本公司 2024 年年度股东大会审议并采用累积投票方 式表决。 特此公告。 广州白云山医药集团股份有限公司 关于补选董事的公告 广州白云山医药集团股份有限公司董事会 本公司及董事会全体成员保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性承担法律责任。 2025 年 4 月 29 日 证券代码：600332 证券简称：白云山 公告编号：2025－037 广州白云山医药集团股份有限公司（以下简称"本公司"）于 2025 年 4 月 29 日召开了本公司第九届董事会第二十三次会议，审议通过了《关 于提名程洪进先生为本公司第九届董事会执行董事候选人并建议其 2025 年度薪酬的议案》和《关于提名唐和平先生为本公司第九届董事会执行董 事候选人并建议其 2025 年度薪酬的议案》。根据《公司法》等法律法规 和《公司章程》的规定，经本公司控股股东广州医药集团有限公司（"广 药集团"）推荐，本公司第九届董事会提名与薪酬委员会 2025 年第 2 次 会议对上述董事候选人的个人简历、任职资格等进行了审查，本公司董事 会同意提名程 ...